Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain

Taylor, James G., Vikki G. Nolan, Laurel Mendelsohn, Gregory J. Kato, Mark T. Gladwin, Martin H. Steinberg. "Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain" PLoS ONE 3(5): e2095. (2008)
https://hdl.handle.net/2144/2969

Boston University
Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain

James G. Taylor VI1*, Vikki G. Nolan2*, Laurel Mendelsohn1, Gregory J. Kato1,3, Mark T. Gladwin1,3, Martin H. Steinberg2

1 Pulmonary and Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 2 Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America, 3 Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America

Abstract

Background: Intravascular hemolysis in sickle cell anemia could contribute to complications associated with nitric oxide deficiency, advancing age, and increased mortality. We have previously reported that intense hemolysis is associated with increased risk of vascular complications in a small cohort of adults with sickle cell disease. These observations have not been validated in other populations.

Methods: The distribution of serum lactic dehydrogenase (LDH) values was used as a surrogate measure of intravascular hemolysis in a contemporaneous patient group and an historical adult population from the Cooperative Study of Sickle Cell Disease (CSSCD), all with sickle cell anemia. Chronic hyper-hemolysis was defined by the top LDH quartile and was compared to the lowest LDH quartile.

Results: Hyper-hemolysis subjects had higher systolic blood pressure, higher prevalence of leg ulcers (OR 3.27, 95% CI 1.92-5.53, P < 0.0001), priapism (OR 2.62, 95% CI 1.13-6.90, P = 0.03) and pulmonary hypertension (OR 4.32, 95% CI 2.12-8.60, P < 0.0001), while osteonecrosis (OR 0.32, 95% CI 0.19-0.54, P < 0.0001) and pain (OR 0.23, 95% CI 0.09-0.55, P = 0.0004) were less prevalent. Hyper-hemolysis was influenced by fetal hemoglobin and α-thalassemia, and was a risk factor for early death in the CSSCD population (Hazard Ratio = 1.97, P = 0.02).

Conclusions: Steady state LDH measurements can identify a chronic hyper-hemolysis phenotype which includes less frequent vasoocclusive pain and earlier mortality. Clinicians should consider sickle cell specific therapies for these patients, as is done for those with more frequent acute pain. The findings also suggest that an important class of disease modifiers in sickle cell anemia affect the rate of hemolysis.

Introduction

Hemolysis is a pathologic mechanism leading to cardiovascular, pulmonary, gastrointestinal, and renal manifestations in diverse human diseases [1]. Such complications have been attributed to vascular nitric oxide (NO) depletion via direct scavenging reactions with cell free plasma hemoglobin and impaired NO generation due to enzymatic consumption of arginine by red cell arginase I [1–3].

These sequelae are putative risk factors for morbidity and mortality in aging populations with congenital hemolytic anemias like sickle cell anemia (homozygous HBB val6). In adult sickle cell disease, pulmonary hypertension has a high prevalence and mortality [4,5]. A potential mechanism for its development is pulmonary vasoconstriction and cellular proliferation in response to decades of chronic hemolysis associated with reduced vascular NO [1,2,4,6,7]. Priapism and leg ulcers are also associated with markers of hemolysis leading to speculation that these, and perhaps other disease manifestations, like stroke, could also be a consequence of hemolysis-induced NO deficiency [4,7–9]. Prior work from our group reported that hemolysis, as estimated by plasma LDH level and its red cell derived isoforms, might identify a cardiovascular sub-phenotype among adults with heterogeneous forms of sickle cell disease [7].

While prior epidemiologic studies have focused on individual disease manifestations, we hypothesized that the degree of hemolysis is a key determinant influencing a phenomic spectrum of complications that reflect the severity of sickle vasculopathy.
Our objective was to refine our previously reported subphenotype [7], now limited to patients with sickle cell anemia, and to validate the findings in a larger independent population. Using two separate adult populations, we examined the extremes of LDH distributions in sickle cell anemia to determine if intravascular hemolysis represents a unifying phenotype. Our results suggest that chronic excess, or hyper-hemolysis, is associated with a vascular phenotype in adults that is distinguishable from sickle vasoocclusive complications like acute painful events and osteonecrosis, and is associated with premature mortality.

Methods

Study Populations

NIH sickle cell patients evaluated between February, 2001 and June, 2007 were screened for pulmonary hypertension in an NHLBI IRB approved protocol (ClinicalTrials.gov Identifier: NCT00011648) which included written informed consent [4,6,7]. Subject recruitment continued both from local clinics and through media advertisements [4]. Two hundred sixty three sickle cell anemia subjects identified by sequencing the HBB locus, with or without coincident α thalassemia, were included [14]. Data from the Cooperative Study of Sickle Cell Disease (CSSCD; ClinicalTrials.gov Identifier: NCT00005277) was used to independently validate findings. This natural history study followed more than 4000 subjects between 1978 and 1988 [15].

Hydroxyurea treatment was not available, pulmonary hypertension screening by transthoracic echocardiography was not done routinely and measures of intravascular hemolysis and NO physiology were not part of the original protocol. CSSCD patients with sickle cell anemia, with or without coincident α thalassemia, were included in the present study.

Selection of Study Patients (Figure 1)

In NIH patients, LDH values were measured during steady state at initial evaluation with no acute crises or transfusion in the 2 weeks prior to evaluation. No subject had evidence of acute hyper-hemolysis due to crisis, infection or hemolytic transfusion reaction. In CSSCD subjects, we used the median LDH value from steady state measurements taken over 6 years of observation. Patients with ALT values >80 IU were also excluded to avoid confounding by hepatopathy with hepatic LDH elevation. To approximate the demographics of subjects at NIH, and to specifically test the effect of hemolytic rate on cardiovascular complications which evolve with increasing age, CSSCD subjects selected were aged greater than 30 years [4,14]. This age filter generated an older CSSCD study population that was comparable to the NIH; one third of both study populations were comprised of subjects aged more than 45 years (Figure S1). Because the CSSCD recruited patients of all ages, there was an extreme bias towards younger patients without this selection criteria (only 623 or 23% were aged more than 30 years versus 150 or 57% at the NIH.

Figure 1. Selection of adult sickle cell anemia subjects for LDH analysis. Panel A: Selection process in the NIH study that identified subjects with the highest and lowest LDH values. * Includes both sickle cell disease cases and 10 subjects for whom no DNA sample was collected. † Of the 21 subjects excluded from analysis, 14 had an excessive hemolysis index for LDH, 2 had no labs drawn, 4 had ALT values greater than 80 IU/L, and 1 had aplastic anemia. Panel B: Selection in the validation study from the CSSCD. ‡ 172 had ALT values greater than 80 IU/L. § Two were excluded with unexpectedly low LDH values.

doi:10.1371/journal.pone.0002095.g001
P<0.0001). Within each population, LDH was divided into quartiles based on the LDH distribution; the lowest and highest quartiles (representing values greater than the 75th percentile or less than the 25th percentile) were compared in subsequent analyses.

Clinical Definitions

At NIH, acute chest syndrome (ACS) was defined as a patient reported history of one or more episodes of “chest syndrome” or “pneumonia” requiring hospitalization. Stroke was defined by patient reported cerebrovascular disease with some documented by MRI. Osteonecrosis was defined by a history of osteonecrosis of the femoral head or joint replacement. Pain was quantified by average emergency room visits per year for evaluation of severe episodes of acute sickle cell related pain or by categorical comparisons (no annual severe pain episodes versus any severe episodes). In NIH subjects, pulmonary hypertension was defined by tricuspid regurgitant jet velocity (TRV) or N-terminal pro brain natriuretic peptide (NTproBNP) levels as described previously, and severe pulmonary hypertension represented a TRV greater than or equal to 3.0 m/s [4,6]. CSSCD definitions for ACS, stroke, osteonecrosis, and pain are reported elsewhere, and used confirmed clinical criteria [10,13,16,17]. NTproBNP levels were measured in a subset of the CSSCD high and low LDH groups by immunoassay (Elecys Analyzer; Roche Diagnostics, Mannheim, Germany) from stored, frozen plasma samples. Glomerular filtration rate was calculated using the Cockroft-Gault formula [18].

Statistical Analysis

Analyses were performed using Instat (Graph Pad Software, San Diego, CA), Prism (Graph Pad Software), or SAS version 8.2 (SAS Institute, Cary, NC). Comparison of categorical data was by Fisher exact test (2x2 table with 1 degree of freedom) including odds ratios (ORs) and 95% confidence intervals (CIs). Combined analyses were stratified and are reported as Mantel-Haenszel (MH) weighted Odds Ratios and P values derived from MH summary chi-squares. Continuous data were log transformed where appropriate and analyzed by paired t test, Alternate Welch’s t test, or Mann-Whitney test. In this study, P values ≤0.05 were considered significant.

Results

LDH as a Continuous Trait and Chronic Hyper-Hemolysis in the NIH Population

LDH values were examined as a quantitative trait (Figure 2A). For comparison, LDH values from 63 NIH subjects with sequence verified hemoglobin SC disease or sickle β thalassemia (Figure 2B) and 57 healthy African American controls (Figure 2D) demonstrate considerable overlap with values for the NIH sickle cell anemia low LDH group (Figure 2A) [19]. Sixty four sickle cell anemia subjects had LDH values greater than the 75th percentile and 62 had values less than the 25th percentile (Figure 2A, Table 1). Inclusion in the highest LDH quartile defined chronic hyper-hemolysis.

Laboratory characteristics were then compared between LDH groups (Table 1). Subjects with chronic hyper-hemolysis had significantly higher levels of total bilirubin, AST, arginase 1 activity, plasma hemoglobin and plasma vascular cell adhesion molecule-1. This group also had lower hemoglobin concentrations, serum arginine, arginine to ornithine ratios, and fetal hemoglobin (HbF) levels. There were no significant differences in mean HbA levels due to recent transfusion, or in the proportion of subjects who had received episodic red cell transfusion therapy with greater than 5% HbA (Table 1). To determine if the difference in HbF could be attributed to treatment with hydroxyurea, as suggested by the difference in hydroxyurea prescription rates between the LDH groups (Table 2, P = 0.03), all subjects receiving hydroxyurea or with more than 5% HbA (from transfusion) were censored from a second HbF analysis, leaving 63 eligible subjects, 21 each in the high and low LDH quartiles (Table S1). This eliminated any suggestion of an MCV difference (Table S2, P = 0.90), and the mean HbF was again lower in the high LDH group (HbF 0.4±0.4 gm/dl) than in the low LDH group (HbF 0.3±0.5 gm/dl) (Table S2, P = 0.06). This smaller population limited statistical power, but did not change the magnitude of differences between the groups for other labs or clinical complications (Tables S2 and S3).

Clinical Manifestations Associated with Chronic Hyper-Hemolysis in the NIH Population

Hyper-hemolysis clinical characteristics were compared with the low LDH group (Table 2). Chronic hyper-hemolysis subjects had higher systolic blood pressures (P = 0.05) and lower pulse oximetry measurements (P<0.0001). Haptoglobulin was undetectable in hyper-hemolysis patients compared to 5 subjects with measurable levels among low LDH subjects (mean 70.6 mg/dl, n = 5, OR 0.07, 95% CI 0.04-1.26, P = 0.02, Table 2). These were 5 of only 6 detectable haptoglobin levels within the NIH population where this was measured (n=198), including one 65 year old female without detectable HbA or prior treatment with hydroxyurea. Chronic hyper-hemolysis subjects had more priapism (P = 0.04), pulmonary hypertension (P = 0.01), severe pulmonary hypertension (P = 0.002), and elevated NTproBNP levels (P = 0.0001). Chronic hyper-hemolysis subjects also had fewer annual emergency room visits for acute painful episodes (P = 0.004). This is consistent with a significantly lower prevalence for hydroxyurea prescriptions (OR 0.40, 95% CI 0.19-0.85, P = 0.03) (Table 2).

Stability of Steady State Hemolytic Rate and Validation in the CSSCD Population

To validate these associations, an independent analysis was performed in the CSSCD. The distribution of median LDH values for 451 subjects identified 113 in the top quartile and 111 in the bottom quartile (Figure 2C). Two subjects in the bottom quartile were excluded due to outlying low LDH values. In addition, a single LDH determination reflected a relatively constant rate of hemolysis in an individual at steady state, based upon analysis of 225 (49%) of the CSSCD subjects with 3 serial LDH measurements (Figure 3; repeated measures of ANOVA, P = 0.66). Subjects with the highest LDH values again had significantly more corroborative evidence of hemolysis and lower HbF levels (Table 1). When the clinical characteristics of the high and low LDH groups were compared, a phenotypic spectrum of complications similar to those identified in the NIH population was observed (Table 2). Among the chronic hyper-hemolysis group, there was a significantly higher systolic blood pressure (P = 0.02), more prevalent leg ulcers (P<0.0001), a lower prevalence of coincident α thalassemia (genotypes αα/-αα and -αα/-αα; P<0.0001), less severe acute pain (P = 0.05) and a lower prevalence of osteonecrosis (P<0.0001). There was also a male predominance in the hyper-hemolysis group (P<0.0001). Because there were significant differences in the sex distribution and HbF levels between LDH comparison groups in the CSSCD (Tables 1 and 2), Odds Ratios were adjusted for sex and/or HbF, where appropriate. Adjustments changed neither the significance nor magnitude of the associations (data not shown).
Clinical Complications in the NIH, CSSCD and Combined Populations

Odds ratios for selected clinical complications comparing LDH groups for the NIH, CSSCD, and combined populations are presented in Figure 4 and Table S4. Combined results show that leg ulcers (OR 3.27, 95% CI 1.92-5.53, P < 0.0001), priapism (OR 2.62, 95% CI 1.13-6.90, P = 0.03) and pulmonary hypertension defined by NTproBNP (OR 4.32, 95% CI 2.12-8.60, P < 0.0001) were significantly more prevalent with chronic hyper-hemolysis, while osteonecrosis (OR 0.32, 95% CI 0.19-0.54, P = 0.0001) and severe pain episodes (OR 0.23, 95% CI 0.09-0.55, P = 0.0004) were less prevalent (Figure 4C). There was no significant difference in acute chest syndrome (OR 0.83, 95% CI 0.49-1.41, P = 0.54) or stroke (OR 1.95, 95% CI 0.85-4.72, P = 0.13). Hyper-hemolysis was also associated with a significantly lower prevalence of α thalassemia (OR 0.33, 95% CI 0.19-0.58, P < 0.0001).

Survival with Chronic Hyper-Hemolysis

High LDH values were associated with higher mortality in the entire NIH cohort [7]. We therefore examined the extremes of hemolytic rate from the CSSCD population for effects of LDH distributions on mortality. Chronic hyper-hemolysis was associated with earlier mortality in the CSSCD population (Figure 5, Hazard ratio 1.97, 95% CI 1.14-3.41, log-rank test P = 0.02), where the mean follow-up was 10.2 years.

Discussion

Identification of genetic variants underlying human disease has become a priority [20]. A major limitation for genetic studies is that phenotypes defined by a medical diagnosis are often imprecise. This recognition led to a proposed Human Phenome Project, where phenomics would examine both inter-individual variability in newly recognized phenotypes and correlations between different subphenotypes within a single disease [21]. We propose that chronic intravascular hyper-hemolysis represents a novel sickle cell anemia subphenotype. Its identification might be helpful for locating disease modifying factors and developing new therapeutic strategies.

Sickle cell anemia is a prototypical hemolytic disorder. Nevertheless, the degree of hemolysis varies among patients and...
its intensity is modulated by HbF expression and co-incident α thalassemia. It is also likely to be influenced by other genes important in sickle cell pathophysiology. Based on an analysis of steady state LDH distributions in nearly 700 adults with sickle cell anemia, chronic hyper-hemolysis represents a phenotype in independent populations who were recruited originally for different purposes during different therapeutic eras. Individuals with hyper-hemolysis had less frequent vasoocclusion pain and priapism, higher systolic blood pressure and more pulmonary hypertension. Earlier mortality also characterized hyper-hemolysis. Unexpectedly, hyperhemolysis did not result in significantly more acute chest syndrome, leg ulcers, and reduced mortality [9–13]. Similarly, high levels of HbF are associated with less frequent pain, vasoocclusive pain [10,13,24,26]. Protective associations with priapism and leg ulcers are consistent with effects on bioavailable NO [1,2]. Alpha thalassemia was significantly less prevalent among those with hyper-hemolysis further implicating effects on NO as a potential mechanism underlying these associations. Alpha thalassemia is a known genetic determinant that lessens HbF expression and co-incident α thalassemia. These findings provide additional insight into some of the factors that affect severity and overall survival, and could impact indications for treatment.

### Table 1. Laboratory Characterization of the High and Low Hemolysis Phenotypes of Sickle Cell Anemia.

| Parameter                      | NIH High LDH | NIH Low LDH | P value* | CSSCD High LDH | CSSCD Low LDH | P value* |
|--------------------------------|--------------|-------------|----------|----------------|---------------|----------|
|                                | Mean (SD) or No. (%) | Mean (SD) or No. (%) |           | Mean (SD) or No. (%) | Mean (SD) or No. (%) |           |
| **Laboratory Characterization** |               |             |          |               |               |          |
| LDH, U/L                       | 610.6 (178.4) | 234.5 (30.5) | <0.0001  | 680.8 (126.8) | 276.0 (49.3) | -        |
| Total bilirubin, mg/dL         | 3.8 (1.8)    | 2.4 (1.4)   | <0.0001  | 3.9 (2.3)    | 2.5 (1.5)    | <0.0001  |
| Direct bilirubin, mg/dL        | 0.7 (0.5)    | 0.4 (0.3)   | <0.0001  | ND            | ND           | ND       |
| ALT, U/L                       | 28.5 (11.1)  | 26.0 (15.8) | 0.02     | 31.2 (19.4)  | 26.1 (16.3)  | 0.08     |
| AST, U/L                       | 56.5 (18.1)  | 33.0 (16.8) | <0.0001  | 58.9 (25.5)  | 34.5 (16.4)  | <0.0001  |
| Hemoglobin, g/dL               | 7.9 (1.5)    | 9.4 (1.6)   | <0.00011 | 8.4 (1.5)    | 8.7 (1.4)    | 0.01     |
| Hematocrit, %                  | 22.4 (5.0)   | 27.7 (4.8)  | <0.00011 | 23.0 (3.6)   | 26.5 (4.2)   | <0.0001  |
| MCV, fL                        | 92.9 (10.7)  | 95.8 (12.6) | 0.16†    | 94.2 (7.8)   | 93.1 (8.7)   | 0.43     |
| Absolute reticulocytes, 10³/L | 275.2 (130.2)| 230.6 (123.9)| 0.06     | ND            | ND           | ND       |
| Reticulocytes, %               | N/A          | N/A         | ND       | 11.3 (5.1)   | 11.0 (4.9)   | 0.70     |
| Fetal hemoglobin, %           | 6.7 (5.2)    | 10.7 (7.5)  | 0.005    | 5.4 (5.3)    | 6.8 (5.3)    | 0.01     |
| Fetal hemoglobin, g/dL        | 0.6 (0.5)    | 1.0 (0.8)   | 0.0006   | 0.5 (0.5)    | 0.6 (0.5)    | 0.007    |
| Hemoglobin A, %               | 12.5 (20.5)  | 10.1 (18.8) | 0.51†    | ND            | ND           | ND       |
| >5% Hemoglobin A, No. (%)     | 23 (36%)     | 18 (29%)    | 0.41     | ND            | ND           | ND       |
| Arginine, μmol/L              | 39.2 (14.5)  | 45.8 (16.2) | 0.01     | ND            | ND           | ND       |
| Arginine:Ornithine ratio      | 0.67 (0.33)  | 0.82 (0.36) | 0.02†    | ND            | ND           | ND       |
| Arginase 1 activity, μmol/mL/hr| 3.66 (2.76)  | 1.39 (0.70) | 0.001†   | ND            | ND           | ND       |
| Plasma hemoglobin, μmol/L     | 21.2 (18.3)  | 12.1 (15.4) | 0.0003   | ND            | ND           | ND       |
| Plasma VCAM-1, ng/mL          | 1449.9 (773.1)| 966.7 (642.6)| <0.0001  | ND            | ND           | ND       |
| Ferritin, μg/L                | 672 (847)    | 1017 (1352) | 0.25     | ND            | ND           | ND       |
| WBC, 10³/L                    | 10.4 (3.1)   | 10.0 (3.4)  | 0.32†    | 11.5 (2.7)   | 11.4 (2.9)   | 0.80     |
| C-reactive protein, mg/dL     | 0.63 (0.84)  | 0.83 (1.24) | 0.62     | ND            | ND           | ND       |

Abbreviations: NIH, National Institutes of Health; CSSCD, Cooperative Study of Sickle Cell Disease; High LDH, patients with LDH values >75th percentile; Low LDH, patients with LDH values <25th percentile; ND, not determined.

*Unpaired t test with Welch correction.

**Unpaired t test with Mann-Whitney nonparametric test unless otherwise indicated.

DOI: 10.1371/journal.pone.0002095.
effect against individual complications such that an association is only detectable through secondary analysis of closely related traits like hemolysis. Identifying such effects is further complicated by the variable distribution of HbF among F-cells which was not only detectable through secondary analysis of closely related traits such as leg ulcers and priapism. Also, hydroxyurea therapy was not available, while its potential beneficial effects might be evident in the low LDH group at NIH.

Several limitations are inherent to our studies. First, the CSSCD, whose patients were enrolled more than 25 years ago, had only a limited number of older adults. Additional retrospective analysis of infrequent adult complications like stroke is limited by this demographic, although the combined analysis could suggest a trend towards an association between stroke and hemolysis when interpreted in the context of other works. A high proportion of CSSCD subjects were excluded due to an elevated hepatitis B vaccination and screening of blood for hepatitis C. Also, hydroxyurea therapy was not available, while its potential beneficial effects might be evident in the low LDH group at NIH.

Several limitations are inherent to our studies. First, the CSSCD, whose patients were enrolled more than 25 years ago, had only a limited number of older adults. Additional retrospective analysis of infrequent adult complications like stroke is limited by this demographic, although the combined analysis could suggest a trend towards an association between stroke and hemolysis when interpreted in the context of other works. A high proportion of CSSCD subjects were excluded due to an elevated hepatitis B vaccination and screening of blood for hepatitis C.

Also, hydroxyurea therapy was not available, while its potential beneficial effects might be evident in the low LDH group at NIH. Early mortality with hyper-hemolysis was evident with long term follow-up in the larger CCSCD population, and presumably this was due to previously unrecognized pulmonary hypertension as suggested by the higher prevalence of elevated NTproBNP levels. The survival difference was only apparent after 6 years, suggesting
Figure 3. Stability of steady state LDH values from the CSSCD. The stability of steady state hemolytic rate is demonstrated by analysis of 3 serial LDH measurements in 225 CSSCD subjects (repeated measures of ANOVA, P = 0.66). doi:10.1371/journal.pone.0002095.g003

Figure 4. Clinical manifestations associated with hyper-hemolysis in sickle cell anemia. Panel A: Odds ratios and confidence intervals for associations with hemolysis in the NIH study. *= P value ≤0.05; ○ = P value not significant. Panel B: Associations in the CSSCD population. Panel C: Summary odds ratios for associations between hyper-hemolysis and 8 clinical endpoints in a combined analysis of the NIH and CSSCD populations. doi:10.1371/journal.pone.0002095.g004
that longer follow-up at NIH will be necessary to confirm this finding [7]. We have also shown that markers of hemolysis are a disease component forecasting earlier death using network modeling [40].

Chronic hyper-hemolysis can identify individuals at risk for premature mortality who may be treated with hydroxyurea less often than patients with frequent pain, its major clinical indication. Despite prior findings that hydroxyurea has no beneficial effect on pulmonary hypertension, its use has been advocated on the basis of improved erythrocyte survival and experiential treatment in hemoglobinopathy clinics [4,5,41]. Thus, prospective long term clinical trials evaluating the effects of hydroxyurea, transfusion therapy and other innovative treatment modalities focused on preserving NO bioavailability and decreasing hemolysis, cell free hemoglobin and vascular complications are warranted [41–43].

These data support an emerging model for understanding the protean manifestations of sickle cell anemia that could be influenced by either hemolysis-driven vasculopathy or blood viscosity/vasoocclusion [44]. Future genetic studies of this unifying phenotype might provide novel mechanistic insights into pathogenesis and treatment. Clinically, this study further supports the use of steady state LDH measurements to identify sickle cell anemia patients who are at increased risk for earlier mortality and who might otherwise have treatment options overlooked because of infrequent vasoocclusive pain.

Supporting Information

Figure S1   Figure S1 with supplementary data. Found at: doi:10.1371/journal.pone.0002095.s001 (0.10 MB TIF)

Table S1   LDH Quartile Analysis for Untransfused Sickle Cell Anemia Patients Not Taking Hydroxyurea. Found at: doi:10.1371/journal.pone.0002095.s002 (0.03 MB DOC)

Table S2   Laboratories in Untransfused NIH Sickle Cell Anemia Subjects Not Taking Hydroxyurea. Found at: doi:10.1371/journal.pone.0002095.s003 (0.05 MB DOC)

Table S3   Clinical Associations in Untransfused NIH Sickle Cell Anemia Subjects Not Taking Hydroxyurea. Found at: doi:10.1371/journal.pone.0002095.s004 (0.05 MB DOC)

Table S4   Clinical Associations with Hyper-Hemolysis in Sickle Cell Anemia. Found at: doi:10.1371/journal.pone.0002095.s005 (0.06 MB DOC)

Acknowledgments

We thank the investigators of the Cooperative Study of Sickle Cell Disease who obtained clinical and laboratory data and blood samples for DNA-based studies during the first 10 years of that program and Krupa Desai for assistance with plasma hemoglobin and NTproBNP assays.

Author Contributions

Conceived and designed the experiments: MS JT VN MG. Performed the experiments: JT VN GK LM. Analyzed the data: MS JT VN MG GK LM. Contributed reagents/materials/analysis tools: MS MG GK. Wrote the paper: MS JT VN MG GK LM.
References

1. Rother RP, Bell I, Hillmen P, Gladwin MT (2005) The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293: 1633–1642.

2. Reiter CD, Wang X, Tanus-Santos JE, Houg N, Cannon RO, 3rd, et al. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8: 1383–1389.

3. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, et al. (2005) Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294: 81–90.

4. Gladwin MT, Sachev V, Jison MI, Shizukuida Y, Pehan JF, et al. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350: 489–495.

5. Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, et al. (2006) Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 134: 109–115.

6. Machado RF, Anithi A, Steinberg MH, Bondh D, Sachev V, et al. (2006) N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 296: 310–318.

7. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, et al. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulcers, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107: 2279–2285.

8. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH (2005) Hemolysis-associated priapism in sickle cell disease. Blood 106: 3264–3267.

9. Nolan VG, Adeyeye A, Baldwin C, Wang L, Ma Q, et al. (2006) Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 133: 570–578.

10. Castro O, Brambilla DJ, Thorton B, Reindorf CA, Scott RB, et al. (1994) The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 84: 643–649.

11. Koshy M, Entsuah R, Koranda A, Kraus AP, Johnson R, et al. (1989) Leg ulcers in patients with sickle cell disease. Br J Haematol 74: 1403–1408.

12. Platt OS, Brambilla DJ, Rose WF, Milner PF, Castro O, et al. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330: 1639–1649.

13. Platt OS, Thorton BD, Brambilla DJ, Milner PF, Rose WF, et al. (1991) Pain in sickle cell disease. Rates and risk factors. N Engl J Med 325: 11–16.

14. Taylor JG, Ackah D, Cobb C, Orr N, Precy MJ, et al. (2008) Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol 83: 6–14.

15. Gaston M, Smith J, Gallagher D, Flourney-Gill Z, West S, et al. (1987) Recruitment in the Cooperative Study of Sickle Cell Disease. Blood 84: 643–649.

16. Christakis J, Vavatsi N, Hassapopoulos H, Papadopoulos M, Mandraveli K, et al. (1990) Comparison of homozygous sickle cell disease in northern Greece and Jamaica. Lancet 335: 637–640.

17. Kato GJ, Gladwin MT, Hsieh M, Machado R, Taylor J, Little J, et al. (2006) Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 101: 288–294.

18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41.

19. O'Donnell N, Height SE, Dick MC, Rees DC (2008) Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. Br J Haematol 140: 206–209.

20. Collins FS, Green ED, Guttmacher AE, Guyer MS (2003) A vision for the future of genomics research. Nature 422: 835–847.

21. Freimer N, Sabatti C (2005) The human phenotype project. Nat Genet 35: 14–21.

22. Embury SH, Dozy AM, Miller J, Davis JR Jr, Kleman KM, et al. (1982) Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med 306: 270–274.

23. Higgs DR, Aldridge BE, Lamb J, Clegg JB, Weatherall DJ, et al. (1982) The interaction of alpha-thalassemia and homozygous sickle-cell disease. N Engl J Med 306: 1441–1446.

24. Steinberg MH, Rosenstock W, Coleman MB, Adams JG, Platica O, et al. (1984) Effects of thalassemia and microcytosis on the hematologic and vasocclusive severity of sickle cell anemia. Blood 63: 1353–1360.

25. Milner PF, Krauz AP, Seley JJ, Sleeper LA, Dukes KA, et al. (1993) Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res. pp 136–143.

26. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Beautreux R, et al. (1995) Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 86: 776–783.

27. Poillon WN, Kim BC, Rodgers GP, Noguchi CT, Schechter AN (1993) Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci U S A 90: 5039–5043.

28. Dover GJ, Smith KD, Chang YC, Parvis S, Mays A, et al. (1992) Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 80: 816–824.

29. Garner C, Mitchell J, Hazits T, Retnie J, Farrell M, et al. (1998) Haplotype mapping of a major quantitative-trait locus for fetal hemoglobin production, on chromosome 6q23. Am J Hum Genet 62: 1468–1474.

30. Garner C, Silver N, Best S, Menzel S, Martin C, et al. (2004) Quantitative trait loci on chromosome 3q influences the switch from fetal to adult hemoglobin. Blood 104: 2184–2189.

31. Menzel S, Garner C, Gut I, Matsuda F, Yamauchi M, et al. (2007) A QTL influencing F cell production maps to a gene encoding a zine-finger protein on chromosome 2p13. Nat Genet 39: 1197–1199.

32. Alexander N, Higgs D, Dover G, Serjeant GR (2004) Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol 126: 606–611.

33. Ballas SK (1991) Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. Am J Hematol 36: 122–130.

34. Baum BF, Dunn DT, Maude GH, Serjeant GR (1987) The painful crisis of homozygous sickle cell disease. A study of the risk factors. Arch Intern Med 147: 1231–1234.

35. Christakis J, Vavatsi N, Hassapopoulos H, Papadopoulos M, Mandraveli K, et al. (1990) Comparison of homozygous sickle cell disease in northern Greece and Jamaica. Lancet 335: 637–640.

36. Lande WM, Andrews DL, Clark MR, Braham NV, Black DM, et al. (1988) The incidence of painful crisis in homozygous sickle cell disease: correlation with red cell deformability. Blood 72: 2056–2059.

37. French JA 2nd, Kenny D, Scott JP, Hoffmann RG, Wood JD, et al. (1997) Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood 89: 4591–4599.

38. Kato GJ, Hsieh M, Machado R, Taylor J, Little J, et al. (2006) Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol 81: 503–510.

39. Hassan M, Hasan S, Girday S, Alamingi L, Banka A, et al. (2003) Hepatitis C virus in sickle cell disease. J Natl Med Assoc 95: 939–942.

40. Sebastiani P, Nolan VG, Baldwin CT, Abad-Grau MM, Wang L, et al. (2007) A network model to predict the risk of death in sickle cell disease. Blood 110: 2727–2735.

41. Ballas SK, Marcolina MJ, Dover GJ, Barton FB (1999) Erythropoietic activity in patients with sickle cell anemia before and after treatment with hydroxyurea. Br J Haematol 105: 491–496.

42. Lezcano NE, Odo N, Kuutar A, Brambilla D, Adams RJ (2006) Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 37: 1424–1426.

43. Steinberg MH (2008) Clinical trials in sickle cell disease: Adopting the combination chemotherapy paradigm. Am J Hematol 83: 1–3.

44. Kato GJ, Gladwin MT, Steinberg MH (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical complications. Blood Rev 21: 37–47.